prp17 Antibody

What is PRP17 and why is it an important research target?

PRP17 (also known as CDC40) is a critical pre-mRNA splicing factor with established roles in cell division and developmental processes. In yeast (Saccharomyces cerevisiae), PRP17/CDC40 functions as a second-step pre-mRNA splicing factor that plays essential roles in cell cycle progression, particularly at G1/S and G2/M transitions . The protein exhibits remarkable evolutionary conservation, with human PRP17 capable of partially complementing growth defects in yeast prp17::LEU2 mutants . PRP17 demonstrates extensive genetic interactions with other splicing factors including PRP18, PRP16, SLU7, PRP8, and PRP22, highlighting its central role in splicing machinery . In Caenorhabditis elegans, PRP-17 functions downstream of GLP-1 Notch signaling to promote meiotic entry and/or inhibit germ cell proliferation, while also promoting oocyte fate decisions in sex determination . Due to its critical role in fundamental cellular processes, PRP17 antibodies represent valuable research tools for studying splicing mechanisms, cell cycle regulation, and developmental biology.

How does PRP17 influence cell cycle transitions and what techniques can antibodies provide for studying these mechanisms?

PRP17 plays crucial roles in both G1/S and G2/M transitions of the cell cycle. Using temperature-sensitive alleles in arrest/release experiments, researchers have established that G1-synchronized prp17::LEU2 cells arrest at non-permissive temperatures as unbudded haploid cells with significantly reduced levels of CLN1, CLB5, and RNR1 transcripts . This indicates a PRP17 execution point at or prior to Start, the commitment point for cell cycle progression. At the G2/M transition, PRP17 deficiency results in reduced α-tubulin protein levels (a critical mitotic spindle component), which contributes to the benomyl sensitivity of prp17 mutants and their G2/M arrest .

PRP17 antibodies can be instrumental in studying these transitions through:

• Chromatin immunoprecipitation (ChIP) to identify PRP17 associations with specific gene loci during different cell cycle phases

• Immunofluorescence microscopy to track PRP17 localization throughout the cell cycle

• Co-immunoprecipitation to identify cell-cycle-specific protein-protein interactions

• Western blotting to quantify PRP17 protein levels at different cell cycle stages

What experimental evidence demonstrates the conservation of PRP17 function across species?

Reciprocal BLAST analysis has established that C. elegans PRP-17 is orthologous to both yeast and human pre-mRNA splicing factor PRP17/CDC40 . Functional conservation has been demonstrated experimentally, as C. elegans prp-17 can rescue the temperature-sensitive lethality of a null allele of yeast PRP17 . Similarly, human PRP17 protein partially complements growth defects of yeast prp17::LEU2, indicating functional conservation from yeast to humans . This cross-species functionality makes PRP17 antibodies valuable tools for comparative studies across model organisms, allowing researchers to investigate conserved splicing mechanisms.

What are the optimal approaches for designing antibodies against highly conserved splicing factors like PRP17?

Developing antibodies against highly conserved proteins like PRP17 requires careful consideration of several factors:

• Epitope selection: When designing antibodies against conserved proteins like PRP17, researchers should:

  • Target regions with sufficient sequence divergence between species if species-specificity is desired

  • Focus on functionally important domains if studying protein activity

  • Consider accessibility of epitopes in native protein conformations

• Design by mimicking natural protein interactions: This approach has proven effective for other targets by incorporating interaction domains into CDRs. For PRP17, identifying regions that mediate interactions with other splicing factors could inform antibody design that specifically blocks or detects these interactions .

• Hybrid rational design approaches: Combining rational design with display screening methods offers advantages for developing high-affinity antibodies. For PRP17, this might involve:

  • Designing CDRs based on known structural information about PRP17

  • Randomizing flanking residues to optimize binding

  • Introducing constrained loop structures to enhance specificity

• Optimization of CDR residues: Key optimization strategies include:

  • Eliminating residues with unsatisfied polar groups in the binding interface

  • Strategic introduction or removal of charged residues peripheral to contact sites

  • Balancing hydrophobicity and polar interactions to maximize binding affinity

How can antibody stability be optimized for challenging research applications involving PRP17?

For applications requiring highly stable PRP17 antibodies, such as structural studies or harsh experimental conditions, multiple optimization approaches should be combined:

• Knowledge-based approaches: Applying established stability-enhancing mutations based on previous antibody engineering experience

• Statistical methods: Using covariation and frequency analysis of antibody sequences to identify stabilizing mutations

• Structure-based methods: Employing computational tools like Rosetta and molecular simulations to predict positions critical for stability

A comprehensive approach combining these methods has demonstrated remarkable success, with improvements in melting temperature from 51°C to 67°C for a variant with P101D mutation in VH . For PRP17 antibodies intended for applications like immunoprecipitation followed by mass spectrometry or chromatin immunoprecipitation, such stability optimization is particularly valuable.

How can PRP17 antibodies be employed to investigate pre-mRNA splicing of cell cycle regulatory genes?

PRP17 antibodies can be powerful tools for exploring the relationship between splicing and cell cycle regulation through several methodological approaches:

• RNA immunoprecipitation (RIP): PRP17 antibodies can be used to immunoprecipitate PRP17-RNA complexes, followed by RT-PCR or RNA-seq to identify cell cycle transcripts that are directly processed by PRP17-containing spliceosomes. This approach could identify targets like CLN1, CLB5, RNR1, TUB1, and TUB3, which show splicing dependency on PRP17 .

• Splicing reporter assays: By combining PRP17 antibody-mediated depletion or inhibition with reporters for specific introns (like those found in TUB1 and TUB3), researchers can quantitatively assess the intron-specific requirements for PRP17.

• Chromatin immunoprecipitation followed by sequencing (ChIP-seq): This approach can reveal co-transcriptional recruitment of PRP17 to specific genomic loci, providing insights into the coupling between transcription and splicing of cell cycle genes.

• Proximity ligation assays: Using PRP17 antibodies in combination with antibodies against other splicing factors or cell cycle regulators, researchers can visualize and quantify interactions in situ.

What methodological approaches are most effective for studying PRP17's role in G1/S and G2/M transitions?

To investigate PRP17's specific roles in cell cycle transitions, researchers can employ several antibody-dependent methodological approaches:

• Cell synchronization coupled with immunoblotting: By synchronizing cells at different cell cycle stages and performing western blots with PRP17 antibodies, researchers can track PRP17 expression and post-translational modifications throughout the cell cycle.

• Immunofluorescence microscopy time course analysis: This approach allows visualization of PRP17 localization changes during cell cycle progression, particularly at the critical G1/S and G2/M transitions where PRP17 function is required .

• Sequential ChIP (ChIP-reChIP): Using PRP17 antibodies in combination with antibodies against cell cycle regulators, researchers can identify genomic regions where both factors co-localize.

• Targeted protein degradation combined with live cell imaging: Coupling PRP17 antibody fragments with degradation systems allows temporal control over PRP17 depletion while monitoring cell cycle progression.

What are the key considerations for using PRP17 antibodies in different model organisms?

When employing PRP17 antibodies across different model systems, researchers should consider:

Each model system requires specific optimization of experimental protocols, particularly for fixation methods, permeabilization procedures, and antibody concentrations.

How can PRP17 antibodies be used to investigate intron-specific splicing requirements?

Research has demonstrated that PRP17 exhibits differential effects on splicing of specific introns. For example, in yeast, PRP17 is particularly important for the proper splicing of TUB1 and TUB3 transcripts, which encode α-tubulin and contain non-standard introns . This intron specificity is likely a key factor in PRP17's role in cell cycle regulation.

Advanced methodologies for investigating intron-specific requirements include:

• Intron-specific splicing reporters: Coupling PRP17 antibody-mediated inhibition with reporters containing specific introns can reveal the differential requirements for PRP17 across various intron types.

• In vitro splicing assays: Using PRP17 antibodies to immunodeplete splicing extracts, researchers can assess the splicing efficiency of different pre-mRNAs, then rescue activity with recombinant PRP17 to confirm specificity.

• CLIP-seq with PRP17 antibodies: This approach can identify the RNA sequences directly bound by PRP17, revealing potential intron-specific recognition elements.

• Structure-function analysis: Combining PRP17 antibodies that target different functional domains with splicing assays can reveal which portions of the protein contribute to intron-specific recognition.

What are the methodological approaches for investigating PRP17's interactions with other splicing factors?

To elucidate the complex network of interactions between PRP17 and other splicing factors (like PRP18, PRP16, SLU7, PRP8, and PRP22) , researchers can employ several antibody-dependent techniques:

• Sequential co-immunoprecipitation: Using PRP17 antibodies for initial IP followed by western blotting for interacting partners can reveal stable complexes. This can be performed under various conditions to identify context-dependent interactions.

• Proximity-dependent labeling: Coupling PRP17 antibodies with biotin ligases allows the identification of proximal proteins in living cells, revealing both stable and transient interactions within the spliceosome.

• Inhibitory antibody studies: Antibodies targeting specific interaction domains of PRP17 can be used to disrupt specific protein-protein interactions, helping to establish their functional significance.

• Single-molecule approaches: Using fluorescently labeled PRP17 antibodies in combination with labeled splicing factors can reveal the dynamics of complex assembly and disassembly during the splicing reaction.

How might PRP17 antibodies contribute to understanding disease states associated with splicing dysregulation?

Aberrant pre-mRNA splicing is implicated in numerous diseases, particularly cancers where cell cycle dysregulation is common. PRP17 antibodies can contribute to disease research through:

• Comparative immunohistochemistry: Analyzing PRP17 expression, localization, and post-translational modifications in normal versus diseased tissues can reveal alterations in splicing machinery.

• Splice variant profiling: Coupling PRP17 antibody-mediated pulldowns with RNA-seq can identify disease-specific alterations in splicing patterns of cell cycle genes.

• Therapeutic target validation: Antibodies that specifically inhibit PRP17 function in disease models can help evaluate its potential as a therapeutic target in conditions characterized by splicing dysregulation.

• Biomarker development: PRP17 antibodies could be used to develop diagnostic assays for detecting alterations in PRP17 expression or localization that correlate with disease progression.

What are the optimal sample preparation methods for detecting PRP17 in different experimental contexts?

Sample preparation requirements vary significantly based on the intended application:

For all applications, rapid sample processing and maintaining samples at 4°C during preparation helps preserve protein integrity and prevent degradation.

How can researchers troubleshoot common issues with PRP17 antibody applications?

When working with PRP17 antibodies, researchers may encounter several common challenges:

• High background in immunofluorescence:

  • Increase blocking time and concentration

  • Use species-specific secondary antibodies

  • Include additional washing steps with higher detergent concentration

  • Pre-adsorb antibodies with cellular extracts

• Poor signal in western blotting:

  • Optimize extraction method to ensure efficient nuclear protein recovery

  • Try different membranes (PVDF often works better for nuclear proteins)

  • Increase antibody concentration or incubation time

  • Use signal enhancement systems like biotin-streptavidin amplification

• Inefficient immunoprecipitation:

  • Optimize antibody-to-bead ratio

  • Try different antibody immobilization strategies

  • Adjust salt and detergent concentrations to reduce non-specific binding

  • Consider using tagged PRP17 versions for difficult applications

What validation methods should be employed to confirm PRP17 antibody specificity?

Rigorous validation is essential for ensuring antibody specificity and reproducibility:

• Genetic validation:

  • Testing in PRP17 knockout/knockdown cells or organisms

  • Rescue experiments with recombinant PRP17

  • Testing against related family members to confirm specificity

• Biochemical validation:

  • Western blot showing a single band of expected molecular weight

  • Mass spectrometry confirmation of immunoprecipitated proteins

  • Peptide competition assays to confirm epitope specificity

• Functional validation:

  • Antibody inhibition of known PRP17 activities in in vitro splicing assays

  • Immunodepletion followed by rescue with recombinant protein

  • Correlation between antibody staining and other functional readouts

• Cross-validation:

  • Comparison of results using multiple antibodies targeting different epitopes

  • Correlation between antibody detection and mRNA expression

  • Consistency across different experimental techniques